To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects

Nonalcoholic Steatohepatitis (NASH) Clinical Trial

Official title:

A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IMM-H014 Sand the Effects of Food on Pharmacokinetics in Healthy Subjects

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06216041
• Other study ID #: 2022-I-IMM-H014-01
• Status: Recruiting
• Phase: Phase 1
• Start date: December 6, 2023
• Est. completion date: December 1, 2024

Study information

• Verified date: December 2023
• Source: Changchun Intellicrown Pharmaceutical Co. LTD
• Contact: Shiqi Bai
• Phone: 18943642700
• Email: baishiqi[@]intelli-crown.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of IMM-H014 on fasted condition, and characterize PK of IMM-H014 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either IMM-H014 or placebo.

Description:

The study is a randomized, double-blind phase 1 trial including 3 parts: single ascending dose (SAD) part, multiple ascending dose (MAD) part and food effect (FE) part. SAD and MAD parts adopt "sentinel method "which2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort). Subjects in SAD will receive 12.5,37.5,75, 125, 225, 275, 325mg (Cohort 1-4 and Cohort 6-8) once daily respectively. Subjects in MAD will receive 37.5, 75, 125, 175, 225mg (Cohort 9 - Cohort 13) once daily for 7days respectively. FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts "sentinel method ".The treatment in food effect consists of 2 periods, and subjects will receive175mg(SAD Cohort 5) on fasting and postprandial states respectively. There will be a 7-day wash out period between treatment periods. To monitor AEs, record abnormalities (12-lead ECG, Vital signs, Physical examination, Clinical Laboratory), and detect the pharmacokinetics of IMM-H014.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 138
• Est. completion date: December 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Subjects can voluntarily participate in the clinical trial, sign informed consent before the trial, fully understand the trial content, process and possible adverse events, and complete the study in accordance with the requirements of the trial protocol;

2. Subjects can use effective contraceptive methods, such as abstinence, condoms, IUD use, and dual barrier method (such as condom plus diaphragm), within 6 months from the beginning of screening to the last trial drug administration;

3. 18-45 years of age, male and female (including 18 and 45 years);

4. Male weight =50kg, female weight =45kg; Body mass index (BMI) in the range of 18-28 kg/m2 (including the cut-off value); 5)Vital signs and physical examination with normal or abnormal has no clinical significance.

Exclusion Criteria:

1. Clinical history of drug allergy or specific allergic diseases (asthma, urticaria), or known or suspected allergic history to experimental drugs and related excipients;

2. Subjects who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines and health products within 2 weeks before screening;

3. Clinical laboratory examination (blood routine, urine routine, blood biochemistry, coagulation function, virology examination, thyroid function), abdominal color Doppler ultrasound (liver, gallbladder, spleen, pancreas, kidneys, adrenal gland), chest radiography and other abnormalities with clinical significance; Or other clinically significant diseases (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases) within 6 months before screening;

4. Subjects who ate diets (including grapefruit or grapefruit products, pitaya, mango, etc.) that may affect drug metabolism within 7 days before screening, or had strenuous exercise, or the researchers thought that there were other dieters that affected drug metabolism, absorption, distribution, metabolism and excretion;

5. A family history of a first-degree relative (i.e., biological parent, sibling, or child) with a risk factor for tip torsional ventricular tachycardia, or a family history of short QT syndrome, long QT syndrome, sudden unexplained death in youth (less than/etc. 40 years old), or sudden infant death syndrome;

6. Subjects who suffer from hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia or hypocalcemia which are abnormal and clinically significant by the investigator;

7. Presence of clinically significant abnormalities in ECG or QTcF>450ms (corrected according to Frederica formula, the calculation method is QTCF = Qt/(RR 0.33));

8. Creatinine clearance rate < 90mL/min (Creatinine clearance calculation Cockcroft-Gault formula: CrCl = [(140 - age) by weight (kg)] / [0.814 x Scr (umol/L)] or CrCl = (140 - age) by weight (kg) / 72 x Scr (mg/dL), women need to according to the formula calculation results by 0.85);

9. Suffering from chronic or active gastrointestinal diseases, such as esophageal diseases, acute gastritis, gastric and duodenal ulcers, enteritis, active gastrointestinal bleeding, or gastrointestinal surgery, which investigators believe is still clinically relevant;

10. Subjects who had undergone major surgery (excluding diagnostic surgery) in the six months prior to screening, or who will undergo surgery during the study period, or who had undergone surgery that the investigator determines will affect drug absorption, distribution, metabolism, or excretion;

11. Participants who had participated in other clinical trials within 3 months prior to screening (participants can be enrolled if they withdraw from the study before administration of the investigational drug, that is, they have not received the drug);

12. Blood donation or significant blood loss (> 450ml) within 3 months prior to screening;

13. Had a history of alcohol abuse (drinking an average of 14 units of alcohol per week in the 3 months prior to screening (1 unit =360 mL beer or 45mL liquor with 40% alcohol or 150 ml wine), or could not abstinence during the test period, or had a positive alcohol breath test;

14. Smoking more than 5 cigarettes per day in the 3 months before screening;

15. Have a history of drug or drug abuse or urine drug abuse screening positive;

16. Subjects who have special requirements for diet and cannot accept a unified diet;

17. Have dysphagia;

18. Female subjects are lactating or have positive serological pregnancy results.

19. Acute illness or concomitant medication occurred between the screening stage and the administration of the investigational drug;

20. Ingested chocolate, any food or drink containing caffeine or rich in xanthines within 24 hours before first taking the experimental drug;

21. Subjects who taken any alcohol-containing product or a positive alcohol breath test in the 24 hours prior to the use of the study drug;

22. The investigator believes that the subjects are not suitable to participate in the clinical study for other reasons.

Related Conditions & MeSH terms

• Fatty Liver
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis (NASH)

Intervention

Drug:
• IMM-H014
SAD and MAD adopt "sentinel method "which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).
• Placebo
SAD and MAD adopt "sentinel method "which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).
• IMM-H014 ( FE)
FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts "sentinel method ".The treatment in food effect consists of 2 periods.
• Placebo ( FE)
FE part is divided into two groups: 8 subjects will receive IMM-H014 and 2 subjects will receive placebo In group A .All 8 subjects will receive IMM-H014 in group B. Group A adopts "sentinel method ".The treatment in food effect consists of 2 periods.

Locations

Country	Name	City	State
China	The first Bethune hospital of Jilin University	Changchun	Jilin

Sponsors (1)

Lead Sponsor	Collaborator
Changchun Intellicrown Pharmaceutical Co. LTD

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events following oral doses (single, multiple and food effect)of IMM-H014 and placebo	the adverse events are recorded according to the actual occurrence	through study completion, up to 11, 17, 18 days for SAD, MAD, FE part
Primary	Number of participants with abnormal laboratory tests results and abnormal physical exam findings	The data of the clinical research center is collected and analyzed according to the time point of the test flow chart	through study completion, up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	PK parameters: AUClast(AUC0-t)	AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.	Up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	PK parameters: AUCinf(AUC0-8)	AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).	Up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	PK parameters: Cmax	Cmax is defined as the maximum observed concentration of drug in plasma.	Up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	PK parameters: Tmax	Tmax is defined as the time to maximum concentration.	Up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	PK parameters: t1/2	t1/2z is defined as the time to decline half of the drug concentration in plasma.	Up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	PK parameters: CL/F	?z is defined as the ratio between the elimination of compound per unit time and the total amount of compound.	Up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	PK parameters: ?z	?z is defined as the ratio between the elimination of compound per unit time and the total amount of compound.	Up to 4, 10, 11 days for SAD, MAD, FE part
Secondary	Multiple-dose plasma PK parameter: Rac	Rac (Accumulation Index) is defined as the ratio between AUC0-XX in Day XX and AUC0-XX in Day1	Up to 10 days
Secondary	Multiple-dose plasma PK parameter: DF	DF is defined as the percentage of fluctuation in steady state is 100 * (Cmax, ss - Cmin, ss)/Cavg, ss	Up to 10 days
Secondary	Multiple-dose plasma PK parameter: Cmin	Cmin is defined as the minimum observed concentration of drug in plasma at steady state.	Up to 10 days
Secondary	Multiple-dose plasma PK parameter: Cmax	Cmax is defined as the maximum observed concentration of drug in plasma at steady state.	Up to 10 days